Moderna (MRNA) Earnings: Results, Guidance and Stock Reaction
Moderna's latest report was Q3 2026 on November 6, 2026 (before the open): Crush and a raise, and the stock moved -0.2% on it. Below: the numbers vs Wall Street, then every quarter we've explained in plain English.
Latest: Q3 2026 vs consensus
| Metric | Reported | Consensus | Result |
|---|---|---|---|
| GAAP diluted EPS | $0.38 (vs −$0.51 a year ago) | −$1.25 (LSEG via CNBC) | Beat |
| Revenue | $1.31B (+29%) | $885.1M (LSEG via CNBC) | Beat |
| Net income | $162M (vs −$200M a year ago) | n/a | |
| 2026 revenue growth outlook | 15% to 25% (was up to 10%) | n/a | Raised |
Full MRNA Q3 2026 explainer: what mattered, the reaction and Max's verdict →
Every Moderna report we've explained
- Q3 2026 (November 6, 2026, before the open): Crush and a raise · stock -0.2% after
Get the next MRNA report explained in your inbox.
Every big earnings report in plain English: beat or miss, guidance, and how the stock took it. No spam, unsubscribe anytime.
FAQ
Did Moderna (MRNA) beat earnings last quarter?
In Q3 2026, reported November 6, 2026, Moderna came in Crush and a raise. GAAP diluted EPS: $0.38 (vs −$0.51 a year ago) vs −$1.25 (LSEG via CNBC); Revenue: $1.31B (+29%) vs $885.1M (LSEG via CNBC).
When did Moderna last report earnings?
Moderna reported Q3 2026 results on November 6, 2026, before the open.
Earnings, explained in plain English. Free at 7 AM.
Every morning: who beat, who missed, what the guidance means and how the stock took it, plus 3-month stock calls graded vs the S&P 500.